
    
      This will be an open label clinical study of oral linezolid combination with another oral
      antimycobacterial drug as the maintenance treatment of nontuberculous mycobacterial diseases
      in adult.

      The eligible patients will be treated and monitored for the efficacy and safety every 6 weeks
      until 6 months then every 3 months for a total duration of 18 months.
    
  